A Randomized, Multicenter, Open-label Phase III Study to Evaluate the Efficacy and Safety of Adding Metronomic Chemotherapy of Capecitabine to Standard Adjuvant Therapy for Patients With High Risk HER2-positive Primary Breast Cancer
Phase of Trial: Phase III
Latest Information Update: 03 Aug 2018
Price : $35 *
At a glance
- Drugs Capecitabine (Primary)
- Indications Early breast cancer; Male breast cancer
- Focus Therapeutic Use
- Acronyms SMART
- 25 Jul 2018 Planned number of patients changed from 840 to 794.
- 25 Jul 2018 Status changed from not yet recruiting to recruiting.
- 27 Jun 2018 New trial record